PeptideStack
5.2kquestions
20kanswers
220users

Is a 96.4% result from VendorInvestigate comparable to 99.4% from Janoshik?

Asked 18 Jun 2024Modified 22 months agoViewed 34k times
36

Concretely: 96.4% · VendorInvestigate · 99.4% · Janoshik.

I would like the axes of comparison first and the recommendation second.

I have tried the first option and it works; the question is whether the second is better rather than merely different.

What is the actual trade-off, and does it matter at the scale I am working at?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
reference-standard
reference-standard

Certified reference materials and in-house standards: traceability, the certificate of the standard itself, system suitability, and why every…

179 questions
shareeditfollowflag
SB
askeds_bhattacharya42k3818 Jun 2024

5 Answers

Accepted answer first, then by votes
74

Accepted answer

The single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
KN
answered · acceptedklara_novotna16k166 Oct 2024
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
67

Worth being precise here: identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

More usefully, gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
C8
answeredcoldpack_8837k3825 Sept 2024
32

Stated carefully, area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
IB
answeredilaria_bertone43k383 Sept 2024
6Confirming from the other direction: I did the wrong thing and got exactly the predicted outcome. – mz_4113 17 days ago
5Is there a reason to prefer the second method over the first, other than cost? – dead_volume 9 months ago
add a comment
21

Mechanically, read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
DO
answeredDr_Malik_Osei37k3812 Jul 2024
3For what it is worth, my own result was within half a per cent of this. – w_okoye 7 months ago
4Any reason this would differ for a longer peptide? – lyoph_cake 9 months ago
add a comment
-1

To be exact about it, start from what the detector sees, because that tells you what the number means.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
ED
answerede_dziedzic87k24814 Sept 2024
4Is there a reason to prefer the second method over the first, other than cost? – Dr_Bram_Verhoeven 7 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.